Your Cart
Your cart is empty

Looks like you haven't added any test / checkup to your cart

Add Test / Checkup
User Sign In Health checkup offers
Lab Test

FLT3 Gene Mutation (ITD, D835Y) Detection

FLT3 Gene Mutation (ITD, D835Y) Detection

Fms-like tyrosine kinase 3 (FLT3) gene mutation is one of the most common genetic alterations in Acute Myeloid Leukemia (AML), occurring in approximately one-third of patients. There are two main types of FLT3 mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain (TKD), including D835Y. FLT3-ITD mutations are associated with high relapse rates and poor overall survival, whereas the prognosis related to FLT3-TKD mutations is less clear. Identifying these mutations is essential for prognosis and therapeutic decisions in AML.

  • Test NameFLT3 Gene Mutation (ITD, D835Y) Detection
  • Sample TypePeripheral blood/Bone Marrow
  • Preparations RequiredThere are no specific preparations required for this test. However, the patient should inform the doctor about any ongoing medication or health conditions.
  • Report Time12 days

What is the FLT3 Gene Mutation (ITD, D835Y) Detection test?

This is a genetic test used to detect mutations in the FLT3 gene, specifically ITD and D835Y, commonly found in Acute Myeloid Leukemia (AML) patients. This test plays a significant role in prognosis and determining treatment strategy.

Why is this test performed?

The FLT3 gene mutation test is performed to guide the prognosis and treatment options for AML patients. Patients with FLT3-ITD mutations are often at a higher risk of relapse and have a poorer overall survival rate.

Home Sample Collection Process

Book your convenient slot
Book your convenient slot
Sample Collection by Phlebotomist
Sample Collection by Phlebotomist
Reporting of the sample at lab
Reporting of the sample at lab
Download Reports
Download Reports
Frequently Asked Questions

The test requires a sample of the patient's peripheral blood or bone marrow, which is then subjected to a genetic testing process, usually PCR or Next Generation Sequencing (NGS), to identify any mutations in the FLT3 gene.

Positive results indicate the presence of FLT3-ITD or D835Y mutation, which can guide clinicians in deciding on the most suitable treatment strategy. FLT3-ITD mutations are associated with aggressive disease and poorer prognosis, whereas the implications of D835Y mutation on prognosis are less clear.

No special preparation is required for this test. However, the patient should always inform the doctor about any ongoing medications or health conditions.

This test is typically done at the time of AML diagnosis to guide initial treatment decisions. However, it might also be repeated at relapse to evaluate the potential for targeted therapy.

The quality of the sample and the timing of sample collection can affect the test results. Furthermore, concurrent medical conditions or recent blood transfusions might also impact the test outcomes.

If the test results are abnormal, the patient should consult a hematologist or an oncologist specializing in leukemia.

The risks associated with this test are minor and relate to the collection of the blood or bone marrow sample. These may include slight pain, light-headedness, or minor bleeding at the puncture site.

An abnormal result, specifically the presence of FLT3-ITD or D835Y mutation, indicates an altered prognosis and can influence treatment strategy. It can also qualify patients for targeted therapies.

Treatment options for AML depend on various factors, including the type of AML, the patient's overall health, and specific genetic changes. They can range from chemotherapy, targeted therapies (especially for patients with FLT3 mutations), immunotherapy, to stem cell transplantation.

Research efforts have been focused on finding effective FLT3 inhibitors, given the poor prognosis associated with FLT3-ITD mutations. Midostaurin was the first multi-kinase inhibitor approved for FLT3-mutated AML. More recently, more selective inhibitors such as gilteritinib and quizartinib have shown promising results in clinical trials. Ongoing research aims at improving the efficacy and reducing the side-effects of these targeted therapies.

FLT3 gene mutation detection, specifically ITD and D835Y, is crucial for risk stratification and treatment planning in AML patients. By identifying the presence of these mutations, clinicians can choose the most effective treatment strategies, including targeted therapies, thereby improving the overall outcomes. Therefore, patients should discuss the implications of this test with their healthcare provider to understand its relevance in the context of their overall disease management.

FLT3 Gene mutation (ITD, D835Y) Detection
₹ 5500 Add to Cart
Schedule Test in Your Available Time
Locations Near You in Hyderabad
  • 4KM from Madhapur
  • 3KM from Banjara Hills
  • 1.9KM from Yusufguda
  • 3KM from Madhura Nagar
  • 5KM from Shaikpet